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Abstract
MicroRNAs are key regulators of various fundamental biological processes and, although representing only a small
portion of the genome, they regulate a much larger population of target genes. Mature microRNAs (miRNAs) are sin-
gle-stranded RNA molecules of 20-23 nucleotide (nt) length that control gene expression in many cellular processes.
These molecules typically reduce the stability of mRNAs, including those of genes that mediate processes in
tumorigenesis, such as inflammation, cell cycle regulation, stress response, differentiation, apoptosis and invasion.
MicroRNA targeting is mostly achieved through specific base-pairing interactions between the 5’ end (‘seed’ region)
of the miRNA and sites within coding and untranslated regions (UTRs) of mRNAs; target sites in the 3’ UTR diminish
mRNA stability. Since miRNAs frequently target hundreds of mRNAs, miRNA regulatory pathways are complex.
Calin and Croce were the first to demonstrate a connection between microRNAs and increased risk of developing
cancer, and meanwhile the role of microRNAs in carcinogenesis has definitively been evidenced. It needs to be con-
sidered that the complex mechanism of gene regulation by microRNAs is profoundly influenced by variation in gene
sequence (polymorphisms) of the target sites. Thus, individual variability could cause patients to present differential
risks regarding several diseases. Aiming to provide a critical overview of miRNA dysregulation in cancer, this article
reviews the growing number of studies that have shown the importance of these small molecules and how these
microRNAs can affect or be affected by genetic and epigenetic mechanisms.
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MicroRNAs: Characterization and Biogenesis
MicroRNAs (miRNAs) are a group of small RNAs,
with around 19 to 25 nucleotides, resulting from cleavage
of larger non-coding RNAs. They act as post-transcriptio-
nal regulators of gene expression, both in plants and in ani-
mals (Bartel, 2004). In 1993, the first miRNA, named lin-4
(lineage-deficient-4), was discovered in Caenorhabditis
elegans, and was found to be associated with regulation of
larvaldevelopment.ThesecondmiRNA,let-7,wasdiscov-
ered in 2000, also in Caenorhabditis elegans. The funda-
mental discovery of the regulatory processes governed by
miRNAswasamajorstimulusforthescientificcommunity
andledtoalargenumberofimportantresearchonmiRNAs
(Ambros, 2003). Over the last seven years, more than 4500
of miRNAs have been identified in the genomes of nema-
todes, flies, plants, viruses and humans. It has been esti-
mated that more than 1000 miRNAs exist in the human ge-
nome. Estimates suggest that miRNA regulatory processes
may modulate the expression of 1 to 4% of human genes,
thus making miRNAs one of the largest classes of genomic
regulators (Calin et al., 2004).
In mammals, miRNAs have been associated with
diverse molecular pathways including regulation of prolif-
eration, apoptosis, differentiation, cell cycle regulation
hematopoiesis, and many more cellular processes. Recent
studies have emphasized the importance of understanding
the mechanism of mRNA regulation by studying changes
in miRNA expression in a variety of human pathological
conditions, including cancers (Vanderboom et al., 2008).
Given their importance in development, it was to be ex-
pected that miRNAs would also have a significant role in
tumorigenesis. Since their discovery close to 3000 publica-
tions,includingover700reviews,documentedassociations
between miRNAs and cancer, (Garofalo and Croce, 2010;
Medina and Slack, 2008).
The miRNAs of different organisms have very simi-
lar overall patterns of three-dimensional structure, even
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Review Articlethough they frequently differ significantly in their precise
cellular functions (Miyoshi et al., 2010). The biogenesis of
miRNAs begins with their transcription by RNA polymer-
ase II, generating a long primary transcript (pri-miRNA)
withacap5’startandapolyAtail.Thistranscripthasasec-
ondary hairpin-shaped structure and while still in the nu-
cleus it is cleaved by RNaseIII and Drosha and their
cofactorDGCR8(DiGeorgeSyndromecriticalregiongene
8), thus generating a precursor molecule of approximately
70nucleotides.Thepre-miRNAisthenquicklytransported
to the cytoplasm via exportina-5 (Exp5), a nuclear exporta-
tion protein that makes use of Ran-GTP as a cofactor.
Once in the cytoplasm, the pre-miRNA is processed
by RNase III and Dicer, thereby generating a double strand
of miRNA, of approximately 22 nucleotides in length. This
product binds to the RISC complex (an induction complex
for RNA silencing) and directs sequence-specific cleavage
of target mRNAs Altyernatively, the miRNA may repress
translation by remaining bound to the mRNA, thereby im-
peding its translation (Figure 1). Such transcriptional re-
pression has been shown to play an important role in regu-
lating growth and differentiation (Ambros, 2003; Medina
and Slack,, 2008), and abnormal expression of components
of the miRNA regulatory complex has been correlated with
different human tumors (discussed below).
Post-transcriptional regulation by miRNAs at the un-
translated 3’ region depends on the extent of sequence
homology with the target mRNA (“templates”), and this
may influence either inhibition of translation of the tem-
plate, or facilitate degradation of the mRNA target tran-
script. Imperfect matching with mRNA leads to variable
inhibitionoftranslationofthetarget,andthismechanismis
the main mode of action of miRNAs in mammals. The ob-
servation that miRNAs are typically short sequences that
can act without the need for complete matching means that
a single miRNA can regulate many target mRNAs. The
converse also holds, so that individual miRNAs may coop-
erate and collectively control one single mRNA target (Ca-
lin et al., 2004).
The molecular biology of miRNAs and how they de
facto act in organisms is still only beginning to be under-
stood. There is a growing number of studies that reveal the
importance of these small RNAs in diverse biological pro-
cesses. Moreover, through the overall regulation of cellular
gene expression and associations with different functional
pathways it has become clear that miRNAs may be in-
volved in various human diseases.
Regulation of Gene Expression Through
MicroRNAs and Implications for Cancer
The current challenge is to identify target transcripts
and pathways that are regulated by miRNAs. Studies have
shown that a single miRISC complex may bind to more
than 200 target genes, which may have a variety of func-
tions, such as transcription factors, receptors and transport-
ers. Thus, miRNAs can control the expression of almost
one third of the human mRNA population, and deletions or
modifications in this expression may contribute towards a
variety of diseases, as well as disrupt pathways of funda-
mental importance in neoplasia (Miyoshi et al., 2010).
Cancer is a complex genetic disease involving
changesinstructuresandgeneexpression.Foralmostthree
decades,carcinogenesishasbeenprimarilyattributedtoab-
normalities in oncogenes and tumor-suppressing genes. It
is now recognized that miRNA also have a primary role in
cancer onset and progression. Oncomir is the term used to
describe an miRNA involved in cancer. Such miRNAs
wereinitiallylinkedtotumorigenesisduetotheirproximity
to chromosomal breakpoints (Calin et al., 2004b) and their
dysregulated expression levels in many malignancies (Ca-
lin et al., 2004a). Abnormal gene expression by miRNAs
has been correlated with several types of tumors, and such
genes may function as oncogenes or tumor-suppressing
genes (Figure 2). In humans, 50% of the miRNA genes are
located at genomic sites associated with cancer-specific
chromosomal rearrangements. A prime example are the
genes miR-15 and miR-16, which are located on chromo-
some13q14,aregionthatisdeletedinmorethanhalfofthe
cases of chronic lymphocytic leukemia and B-cell leuke-
mia (Calin et al., 2002). It has also been reported that
miR-15a and miR-16-1 negatively regulate the expression
of BCL2, an anti-apoptotic oncogene that is generally
overexpressed in a variety of tumors, including leukemias
andlymphomas(Calinetal.,2008).Thesefindingssuggest
that miR-15a and miR-16 may act as tumor-suppressing
genes in human cancer.
The miRNAs that code for the let-7 family were the
first group of oncomirs identified. These regulate the ex-
pressionofoncogenes,andspecificallytheRASgenes.Mu-
tations of the RAS oncogene are present in around 25%-
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Figure 1 - The biogenesis and function of miRNAs.30% of all human tumors, and overexpression of the RAS
oncogene is very common in lung cancer cases. Ras pro-
teins are membrane proteins that regulate cell growth and
differentiation through MAP kinase signaling. In vitro ex-
periments on a pulmonary adenoma cell lineage showed
that let-7 was able to inhibit cell proliferation though Ras,
inferring that let-7 may function as a tumor suppressor in
this context (Johnson et al., 2005). Thus, the let-7 miRNA
that regulates the expression of the Ras protein is also able
to indirectly alter the cell proliferation rate through its
downstream MAP signaling cascade.
The strongest evidence for an association between
miRNAs and cancer was demonstrated by a sequence of
three concurrent studies published in Nature in June 2005
(Heetal.,2005;Luetal.,2005;O’Donnelletal.,2005).The
MYC oncogene, which codes for a transcription factor and
functions as a cell growth regulator to induce proliferation
and apoptosis, frequently appears mutated or amplified in
human tumors. These authors reported that the miRNA
groupmiR-17-92(composedofsevenmiRNAs:miR-17-5p,
miR-17-3p, miR-18, miR-19a, miR-20, miR-19b-1 and
miR-92-1) was deregulated leading to increased expression
ofMYC,culminatingwithdevelopmentofB-cellneoplasia.
Recent studies have demonstrated that the expression
levels of miR-143 and miR-145 are significantly lower in
colorectal tumors, thus suggesting that these miRNAs act as
potential tumor suppressors (Arndt et al., 2009). Several
classes of deregulated miRNAs have also been shown to be
differentially expressed in breast cancer, compared with
healthybreasttissue(Voliniaetal.,2006).Moreover,theex-
pression signatures of informative miRNA subsets have en-
abled better molecular classification than mRNA expression
profiles in several types of human cancer (Lu et al., 2005).
Among the miRNAs differentially expressed in
breast cancer, miR-10b, miR-125, miR-145, miR-21 and
miR-155 have consistently presented the highest degree of
deregulation. Downregulation of miR-10b, miR-125b and
miR-145 and upregulation of miR-21 and miR-155 suggest
that these miRNAs may play an important role as tu-
mor-suppressors or oncogenes (Blenkiron et al., 2007). In
particular, the miR-145 miRNA is progressively downre-
gulated when passing from healthy breast tissue to breast
cancer with high cell proliferation rates. Similarly, but in
theoppositedirection,theexpressionofmiR-21isprogres-
sively upregulated when comparing normal breast tissue
with breast cancer at advanced stages. Thus, the deregula-
tion of these miRNAs may affect molecular events that are
critical for tumor progression (Yang et al., 2008).
Some specific miRNAs have also been associated
withtumorinvasionandmetastasisinbreastcancer.Forex-
ample, the level of miR-10b expression in primary breast
carcinomashasbeencorrelatedwithclinicalprogressionof
the disease (Ma et al., 2007). Recently it was also observed
that the expression of miR-7, miR-128a, miR-210 and
miR-516-3p was associated with aggressiveness in cases
that were positive for estrogen-receptor tumors and nega-
tive for lymph node tumors (Foekens et al., 2008).
In recent years, studies on miRNAs, especially on a
large scale using microarrays, have provided a more com-
prehensive picture on the role of abnormal miRNA expres-
sion in neoplasia. Upon using molecular profiling methods
such as bead-based flow cytometry, real-time PCR or mi-
RAGE (SAGE analysis) it became possible to determine
tissue-specific “signatures” for miRNAs. In line with this,
novel molecular classifications of tumors based on their
miRNA expression, have provided a wealth of new re-
sources for predictive and prognostic biomarkers for clini-
cal applications in cancer.
Association Between SNPS at MicroRNA
Binding Sites and the Risk of Cancer
When a sequence polymorphism is present within a
miRNAtranscriptitiscalledamiR-SNP.ThesemiR-SNPs
are single-base polymorphisms (SNPs) in the miRNA se-
quences and are considered to be an important new class of
functional polymorphisms in the human genome. Since the
mode of action of miRNA is highly sequence-dependent,
changing a single base in a miRNA sequence that alters
binding specificities may affect multiple genes, thus im-
pacting on one or several biological pathways.
ThefunctionofmiRNAsmaybealteredthroughvari-
ations in their own sequence (miR-SNPs) or in their target
sequences (called “miR-TS-SNPs”) (Figure 3). Since a sin-
glemiRNAcanhavemultiplemRNAtargetsites,sequence
polymorphisms in general have deeper and more extensive
effectsfromabiologicalpointofviewthanwouldsequence
alterations to mRNA (Sun et al., 2009). Duan and Pak
(2007) identified a SNP within an essential region of miR-
125 that significantly changed the miR-125a sequence and
abolished recognition of its target site. Functional experi-
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Figure 2 - MicroRNAs (miRNAs) as tumour suppressors and oncogenes.
Downregulation or loss of miRNAs with tumour suppressor function may
increase translation of oncogenes and hence formation of excess onco-
genic proteins, leading to tumour formation. In contrast, upregulation of
oncogenic miRNAs may block tumour suppressor genes and also lead to
tumour formation.ments in vivo confirmed that the presence of this polymor-
phismblockedthematurationofmiR-125a.Anotherexam-
pleofthisprocessisaSNPintheprecursorofmiR-K5,that
is encoded by the human herpes virus in association with
Kaposi’s sarcoma. This polymorphism correlated with ab-
normalities in the miRNA cleavage processing by the Dro-
sha enzyme. Similarly, Yang et al (2008) analyzed 41
potentially functional polymorphisms in miRNAs, pre-
microRNAs and pri-microRNAs that predisposed to blad-
dercancer(Yangetal.,2008)andfoundaSNPinGEMIN3
geneandacommonhaplotypeinGEMIN4thatshowedsig-
nificant associations with higher risk of bladder cancer.
Moreover, it could be demonstrated that combinations of
certaingenotypeswerestronglyassociatedwithpredisposi-
tion towards bladder cancer, and that the presence of these
specific miRNA genotypes could be used as a tool for pre-
dictingtheriskofdevelopingsuchtumors.Theseexamples
illustrate that variations in the different biogenesis routes
formiRNAsaffecttheirownfunctionandconsequentlythe
expression of the target messenger RNA.
One of the first epidemiological studies showing a re-
lationship between polymorphisms in the binding region of
miRNAs and cancer was published by Landi et al (2008),
wherein a relationship between the allele variants of CD86
(polymorphism rs17281995, C > G) and the microRNAs
miR-337, miR-582, miR-200a, miR-184 and miR-212 was
found to lead to a higher risk of colorectal cancer. It was
alsoshownthatthereisarelationshipbetweenthepresence
of polymorphism rs1051690 in the insulin receptor (INSR)
andahigherriskofcolorectalcancerduetomodificationof
the binding affinity of the miRNAs 618 and 612 (Landi et
al., 2008). Subsequently, a SNP was identified at the target
site of let-7 in the 3’UTR region of the KRAS gene (LCS6-
KRAS) (Trang et al., 2008). The presence of this polymor-
phism was associated with increased risk of lung cancer
among smokers. This allele variant was detected in 20% of
the patients with lung carcinoma (NSCLC – non-small cell
lung carcinoma). In asymptomatic individuals, LCS6-
KRAS was found in 6% of the sample analyzed (n = 2433).
In a case-control study on lung cancer, the presence of this
allele was associated with an increased risk of lung cancer
(relative risk of 2.3) among individuals with a history of
smoking (mean of 820 cigarettes/year). Functional studies
demonstrated that the presence of this polymorphism di-
minished the binding affinity of let-7 to its target site in
KRAS, and consequently, increased expression of KRAS.
Nonetheless, Christensen et al (2009) reported that in head
and neck cancer, this same polymorphism (LCS6-KRAS)
was not associated with any general increase in cancer risk,
but significantly so with reduced survival (Christensen et
al., 2009). Amongst the polymorphisms affecting miRNA
target sites, Tchatchou et al (2009) analyzed a group of 11
SNPs and found a strong correlation between the variant
rs2747648 (C/T) in the estrogen receptor 1 (ESR1) gene
and an increased risk of breast cancer. This risk was shown
tobehigherforpremenopausalwomenwithapositivefam-
ily history of cancer (Tchatchou et al., 2009). The mode of
action was inferred to be due to a lower binding affinity of
miR-453inthepresenceoftheTallele,andconcomitantre-
ducedrepressionoftheESR1gene.Sincelossofbindingof
miR-453, led to overexpression of both the ESR1 mRNA
and its receptor protein, the breast cancer cancer risk is ex-
pected to be increased.
Taken together the regulation and role of miRNAs
and the large number of target sites in functionally impor-
tant genes and associated pathways provides new insights
into cancer risk. It is clear that both a single miR-SNP or a
specific combination of miRNA gene variants may act to-
getherontheirtargetmRNAsitestoconstituteanewprevi-
ously unappreciated mechanism for predisposition to
cancer.
Association Between Epigenetic Alterations and
MicroRNAs in Cancer
Various epigenetic alterations may take place during
tumor development. Recent studies have indicated that
miRNAexpressioncanberegulatedbydifferentepigenetic
mechanisms, including changes in DNA methylation in
promoter regions and histone modification (Scott et al.,
2006;Esteller,2008)(Figure4).Thisderegulationseemsto
involve hypermethylated CpG islands that map close to
specificmiRNAs.WhenexpressionofsuchamiRNAisaf-
fected, any methylation of this area will simultaneously al-
ter the expression of any target mRNA and proteins
modulated by the epigenetically modified miRNA (Scott et
al., 2006).
Recent studies involving epigenetic factors and
changes to miRNA expression have mostly been restricted
to assays on tumor cells. One of the first studies to be pub-
lished involved miR-127, which acts to repress the tu-
mor-specific expression of the proto-oncogene BCL-6.
After treating tumor cells with chromatin modifying
agents, miR-127 showed activity in different types of hu-
man cancer cell lines, inferring that its inactivation in these
cells could involve chromatin-induced epigenetic alter-
ations (Saito et al., 2006).
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Figure 3 - Possible mechanism for SNP within 3’UTR region of the mes-
senger RNA (mRNA) target gene.Suppression of hsa-miR-9-1, hsa-miR-129-2 and
hsa-miR-137 in colorectal cancer is, at least partly, medi-
ated by epigenetic mechanisms such as DNA hypermethyl-
ationandhistonedeacetylation,asdemonstratedinarecent
study by Bandres et al (2009). This study also emphasized
that frequent hypermethylation of these miRNA loci in
colorectal cancer was correlated with clinicopathological
abnormalities. Expression of hsa-miR-9-1 was associated
with positive lymph node biopsies in patients with ad-
vanced stages of colorectal cancer. DNA methylation was
considered to be the most likely mechanism for diminish-
ing or inhibiting the expression of these specific miRNAs.
Considering that these miRNAs are not usually expressed
in normal mucosal tissue, this epigenetic alteration would
diminish the tracking of disease evolution (Bandres et al.,
2009).
Inbreastcancercellcultures,thehomozygousvariant
of the miRNA hsa-miR-196a-2 (rs11614913, CT) was
shown to be significantly associated with diminished risk
of breast cancer, and hypermethylation of a CpG island lo-
cated 700 base pairs above the precursor region of
miR196a-2 led to a reduction in the risk of breast cancer
(Hoffmanetal.,2009).Basedonaseriesofmolecularanal-
yses, these authors suggested that miR-196a-2 might have
oncogenic potential in breast cell tumorigenesis, and that
functional genetic variations in this miRNA could serve as
biomarkers for susceptibility to breast cancer.
Lodygin et al. (2008) reported that miR-34a expres-
sion was consistently silenced in different types of cancer
by aberrant methylation of CpG in the promoter region
(Lodygin et al., 2008). It was shown that 79.1% of primary
prostatecarcinomashadCpGmethylationandconcomitant
loss of miR-34a expression. Similar observations with dif-
fering proportions were made in carcinoma cells in breast
(25%), lung (29.1%), colon (13%), kidney (21.4%) and
pancreas tissue (15.7%), and in melanomas (43.2%) and
primary melanomas (62.5%).
Preservation, Expression and Localization of
MicroRNAs in Paraffinized Tissue Samples
Several methods for evaluating miRNA expression
profiles have been implemented, including RT-PCR,
microarrays and serial analysis of gene expression (mi-
RAGE). Independent of the approach, success in applying
these techniques is essentially limited by the availability of
fresh or frozen clinical tissue samples, which are consid-
eredtobethemostreliablesourcesofintegralRNA(Zhang
et al., 2008). Nevertheless, miRNAs turned out to be less
affected by fixation in formalin and embedding in paraffin
than mRNAs because of their slower degradation, smaller
size and lack of a poly-A tail. Good correlations were
denoited formiRNA profiles of RNA extracted from frozen
samples and those embedded in paraffin (Zhang et al.,
2008).
Samples preserved in paraffin are also useful in eval-
uating the action of a miRNA on a target gene and deter-
mining whether it may result in a change in the expression
of the corresponding protein. Changes in the expression of
proteins regulating the biogenesis of miRNA can also be
evaluated at the cellular level. For such analyses, immuno-
histochemical techniques are useful as these make it possi-
ble to detect the location and/or site of subcellular action of
the target protein. As an example, the proteins that bind
RNA LIN28 and LIN28B prevent precursors of miRNA
let-7 from being processed by mature miRNA (Newman et
al., 2008). Using immunohistochemistry and tissue micro-
arrays,LIN28andLIN28Bwerefoundtobeoverexpressed
in colon, breast, lung and cervical cancers. Increased ex-
pression was associated with physiological repression of
let-7 levels and tumor progression, implying a tumor-
suppressing role for this miRNA (Viswanathan et al.,
2009). In addition, the role of miRNA in tumor tissue sam-
ples can be evaluated by means of in situ hybridization
(ISH) tests to measure expression levels of specific
miRNAs in target cells. Recently, a highly sensitive tech-
niquewasdescribedfordetectingsinglemiRNAmolecules
in individual cells (Lu and Tsourkas, 2009). The method
known as LNA-ELF-FISH employs oligonucleotides from
lockednucleicacidswithfluorescenceforsignalamplifica-
tion, thus allowing miRNAs to be spatially located and
quantified inside cells.
In a study on gliomas, and especially multiform glio-
blastomas, the miRNAs regulated by Dicer, miR-222 and
miR-339 were identified using ISH, while the endonu-
clease and the intercellular adhesion molecule ICAM-1
were evaluated by means of immunohistochemistry. These
miRNAs were shown to be expressed by the tumors and
negatively regulated ICAM-1, given that the expression of
these molecules presented inverse associations in the tissue
samples (Ueda et al., 2009). In expression microarrays,
there was no difference in Dicer expression between nor-
mal prostatic tissue and organ-confined prostate cancer.
However, immunohistochemical analysis demonstrated
that in normal tissues, Dicer immunoreactivity was de-
tected only in basal cells, proliferative neoplastic cells, and
in invasive cancer. The redistribution of Dicer among the
cell types seemed to be biologically significant with cancer
progression and metastasis, and the level of this endo-
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Figure4-Crosstalkbetweengenomicmethylation,histonemodifications
and the effects of microRNAs in the gene expression profile.nuclease continued to increase in the abnormal cells (Chio-
sea et al., 2009).
The miR-21 is one of the most-studied miRNAs in
cancercasesanditishighly expressedinbreastcancer.In a
cohortanalysisusingISH,aprogressiveincreaseintheper-
centage of patient tumors positive for miR-21 was ob-
served, from normal breast tissue (13%), flat epithelial
atypia (47%), ductal carcinoma in situ (75%) to invasive
ductal carcinoma (88%). In addition, the expression of
miR-21 target genes such as PTEN, PDCD4 and TM1 was
evaluatedinthesametumorsamplesfromthecohortatcel-
lular level, and the cell transformation suppressor TM1 was
confirmed as a target of miR-21 in breast tumors, present-
ing reduced tissue immunoreactivity with progressive le-
sions, i.e. an inverse relationship with the marker pattern of
miR-21 (Qi et al., 2009).
Despite the fast advances in comprehending the bio-
genesisandactionmechanismofmiRNAs,manyquestions
regarding their function and influence on central signaling
pathways and cell cycle control remain. The complex sto-
chastic nature of gene expression in mammalian cells has
wide-rangingimpactonphenotypicdiversity.Itistherefore
likely that evaluating mean miRNA expression levels in
mixturesofcellpopulationsmayresultinlossofcrucialin-
formation for linking miRNA expression to cellular func-
tions.Thus,thephysiologicalroleofmiRNAinsinglecells
should be more informative in distinguishing the impact of
miRNA on signaling networks and cellular pathways rele-
vant to disease (Lu and Tsourkas, 2009).
Gene Therapy and MicroRNAs
Recently, a new technology of directed artificial-site
miRNAs (templates), for increasing or inhibiting endoge-
nous miRNA regulation was describes (Brown et al.,
2009). This strategy has been used to detect site-specific
target genes in cells, in relation to stem cell therapies and
studies on transgenic animals. Through this highly specific
new approach a promising strategy has emerged, combin-
ing gene therapy with miRNA templates (viruses carrying
the target sequence), in an attempt to fully or partially in-
hibit the expression of these miRNAs.
As described earlier, miRNAs can exert their effects
either by acting as tumor suppressors or through favoring
cancer development (oncomirs). When hyperexpression of
miRNAs contributes towards oncogenesis, the rational
strategy is to reduce their expression. In this regard, inhibi-
tion of specific endogenous miRNAs has been used
through administration of antisense synthetic oligonucleo-
tides, which are complementary to endogenous mature
miRNAs.
Oligonucleotide-modified anti-miRNAs (OMAs),
also known as ‘antagomirs’, currently constitute the major-
ity of miRNA inhibition tools (Soifer et al., 2007). Ba-
sically three different types of OMAs are used for inhibit-
ing miRNAs, these being oligonucleotides with
modifications to the 2-OH group of the ribose residues that
involve replacement with 2’-O-methyl (2’-OMe), 2’-O-
methoxy-ethyl (2’-MOE) or locked nucleic acid (LNA).
These modifications have been incorporated through
knowledge gained from interference RNA techniques
(RNAi), and were essential for offering resistance to enzy-
matic degradation, thereby improving OMA stability when
exposedtothelargequantitiesofnucleasespresentinblood
and the cell environment. Another important structural
change incorporated into these oligonucleotides, with a
view to improving their pharmacokinetic properties (such
as plasma half-life) and increasing the uptake of the mole-
culebycells,wastheintroductionofacholesterolmolecule
in the 3’ terminal region of the nucleic acid (Bijsterbosch et
al., 2000).
Applications of oligonucleotides that specifically in-
hibit oncomirs, such as mir-21, have been demonstrated in
cultures on glioblastoma cells and breast cancer cells,
thereby promoting increased caspase activation and medi-
ating apoptosis in these cells (Chan et al., 2005; Si et al.,
2007). Furthermore, suppression of mir-21 gave rise to sig-
nificant reductions in invasions and lung metastases in cul-
tures on MDA-MB231 breast cancer cells (Zhu et al.,
2008).
The efficacy and significance of several OMAs have
been examined and validated in several pioneering studies
using a model that eliminates miR-122, which is hyper-
expressed in rat livers after administration of specifically
developed OMAs (Krutzfeldt et al., 2005). These authors
werethefirsttodemonstratenontoxiclong-durationsilenc-
ing generated through intravenous injection of ‘antago-
mirs’ (2’-OMe) that were complementary to miR-122, in
mice.
Notwithstanding,oneofthemajorobstaclestoapply-
ing‘antagomirs’inclinicalscreeningisachievingeffective
release of RNAi in the target tissue (Soifer et al., 2007).
Strategies for overcoming these problems have been devel-
oped, for example complexation or covalent bonding of
lipids and/or proteins released in small RNA molecules
(Dykxhoorn et al., 2006). Other alternatives, such as the
use of cationic liposomes and cholesterol, conjugation with
RNA-packaging phages and RNA aptamers that bind to re-
ceptors have been developed to release small RNAs in tar-
get cells (Soutschek et al., 2004). Research on local release
ofbiomoleculesshouldsubstantiallyimprovethetherapeu-
tic opportunities for using miRNAs as targets.
Recently, a new form of miRNAs inhibitors called
“miRNA sponges” were developed which may be transito-
rily expressed in mammal cell cultures (Ebert et al., 2007).
These “miRNA sponges” are transcripts that are under the
controlofstronggenepromoters(RNApolymeraseII)con-
taining tandemly arranged multiple sites for binding to
miRNAs of interest and are capable of inhibiting miRNAs
as strongly as OMAs (Ebert et al., 2007).
368 Palmero et al.For miRNAs that present reduced expression in can-
cer cases, restoration of miRNA levels in the diseased
tissueshouldprovideatherapeuticbenefitthroughreplace-
ment of the target gene regulation. Introduction of dou-
ble-strandedmiRNAs,whichareequivalenttotheproducts
from endogenous Dicer and analogous in structure to a
siRNA (small interference RNA), may provide transient
restoration for underexpressed miRNAs. However, in vivo
application of double-strand mimetic miRNA, resembling
siRNA, still needs to be evaluated.
To achieve greater persistence of miRNA replace-
ment, a transgenic approach is needed so that expression of
specific miRNAs may be induced, starting from a plasmid
or viral vector containing the promoters for both the poly-
merases(IIorIII)thatcontroltheexpressionofashorthair-
pin RNA, which is processed subsequent to the mature
miRNA.
At present only few studies on the use of miRNAs for
in vivo cancer therapy have been published. Gene therapy
based on RNAi has been greatly used over recent years.
Systemic release of siRNA /shRNA (short hairpin RNA)
with an anti-cancer focus employed liposomes, polymers
and nanoparticles. Similar strategies and technologies used
forsiRNAreleaseincellsmayalsobeusedwithmiRNAs.
Conclusion
miRNAs have emerged over recent years as new reg-
ulatory components of the complex mechanisms of gene
expression, with implications for many diseases, including
cancer. Emerging evidence increasingly demonstrates that
miRNAs may also affect or be affected by genetic and
epigenetic mechanisms. In addition, miRNAs and miR-
SNPs are powerful tools for studying disease prognoses
and, in the near future, hold tremendous therapeutic prom-
ise for clinical medicine and for improvements in cancer
control and in curing rates.
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